二、本次交易的进展情况 2026 年 2 月 27 日，中国证券登记结算有限责任公司出具《证券过户登记确认书》， 本次交易已完成过户登记手续，过户日期为 2026 年 2 月 26 日。本次过户登记完成后， 广药二期基金持有南京医药 144,557,431 股无限售流通股，占南京医药目前总股本的 11.04%。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"）召开第九届 董事会第二十九次会议，审议通过了《关于广州广药二期基金股权投资合伙企业（有 限合伙）收购南京医药股份有限公司 11.04%股份的议案》。本公司附属企业广州广 药二期基金股权投资合伙企业（有限合伙）（"广药二期基金"）拟以自有资金通过协 议转让方式收购Alliance Healthcare Asia Pacific Limited持有的南京医药集团股份有限 公司（原南京医药股份有限公司已更名为南京医药集团股份有限公司，简称"南京医 药"）144,557,431 股非限售股份（"目标股份"），占南京医药股份总数的 11.04%（"本 次交易"）。具体内容详见本公司于 2025 年 9 月 29 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合伙）收購南京醫藥集團股份有限公司11.04% 股份的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年2月27日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 海外監管公告 一、本次交易的基本情况 证券代码：600332 证券简称：白云山 公告编号：2026－009 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药集团股份有限公司 11.04%股份的进展公告 本 ...

来源：问董秘 投资者提问： 你好董秘，东方汽车采用了私有化h股，同时换成岚图汽车股份的方式。是因为股价未反应企业价值。 白云山的H股长期低于净资产，也是如此，是否能够采取如同东方汽车的方式，H股进行私有化，同时 换成王老吉的股份。样不仅能体现王老吉的价值，同时也有利于王老吉在全球拓展的影响力。 另外加 多宝谋求在港上市，而王老吉如果能在港上市，无疑是对加多宝的巨大打击。 董秘回答(白云山SH600332)： 尊敬的投资者您好，感谢您的关注和建议！ 查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

Group 1 - The core viewpoint of the article highlights the company's strategy to enhance the value of the Wanglaoji brand by expanding its distribution network and collaborating with major restaurant platforms [1] - The company is focusing on promoting bottled beverages and exploring new product lines, including original flavor herbal tea and various fruit-flavored juice products, to cultivate a second growth curve [1] - In the functional beverage segment, the company has launched Wanglaoji Flash Recharge Electrolyte Water, indicating its commitment to innovation in product offerings [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 關於部分藥品在國家組織集采藥品協議期滿品種接續採購中擬中選的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 证券代码：600332 证券简称：白云山 公告编号：2026-008 广州白云山医药集团股份有限公司 关于部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"公司"）控股子 公司广州白云山天心制药股份有限公司（以下简称"天心制药"）及 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白 ...